Latin American consensus on the supportive management of patients with severe combined immunodeficiency
Severe combined immunodeficiency (SCID) represents the most lethal form of primary immunodeficiency, with mortality rates of greater than 90% within the first year of life without treatment. Hematopoietic stem cell transplantation and gene therapy are the only curative treatments available, and the best-known prognostic factors for success are age at diagnosis, age at hematopoietic stem cell transplantation, and the comorbidities that develop in between. There are no evidence-based guidelines for standardized clinical care for patients with SCID during the time between diagnosis and definitive treatment, and we aim to generate a consensus management strategy on the supportive care of patients with SCID.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Juan Carlos Bustamante Ogando, Armando Partida Gayt án, Juan Carlos Aldave Becerra, Aristóteles Álvarez Cardona, Liliana Bezrodnik, Arturo Borzutzky, Lizbeth Blancas Galicia, Diana Cabanillas, Antonio Condino-Neto, Agustín De Colsa Ranero, Sara Espino Tags: Rostrum Source Type: research
More News: Allergy | Allergy & Immunology | Gene Therapy | Genetics | Primary Immunodeficiency Disease | Stem Cell Therapy | Stem Cells | Transplants